Hangzhou-based medical AI company, MeiYin Intelligence Technology Co., Ltd., recently announced it has secured millions of yuan in seed funding. The funding will primarily be used for R&D and commercialization of its core product. The round was led by Zhuoyuan Asia, with participation from Xihu Government Direct Investment Fund. MeiYin Intelligence focuses on leveraging AI to predict disease risk and promote health management. Its core product, based on its self-developed DP-LLM large model, supports the processing of multimodal medical data to accurately quantify an individual's future disease risk, covering hundreds of diseases and more.
